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【Abstract】Fibrocytes are bone marrow-derived
mesenchymal progenitors that co-express hematopoietic cell
antigens and markers of monocytic lineage as well as fibro-
blast products. During wound healing, fibrocytes have been
found to possess the ability of antigen-presentation to naive
T cells in the inflammatory phase. Moreover, they can pro-
mote the endothelial cell proliferation, migration and angio-
genesis by secreting several proteins. Fibrocytes can fur-
ther differentiate into mature mesenchymocyte lineage, such
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as fibroblasts, myofibroblasts and adipocytes, and they may
represent the systemic source of myofibroblasts that exert a
contractile force required to close tissue wounds. A deep
understanding of the mechanism involved in fibrocyte mi-
gration and differentiation may lead to the development of a
novel theory of normal physiology and pathology.
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Following trauma and disruption of tissue integrity,several overlapping events will be involved, including inflammation, cell  proli feration,
migration, angiogenesis and extracellular matrix mol-
ecule (ECM) production.1 In the inflammatory phase,
various circulating cells are recruited into the injury sites,
such as neutrophils and macrophages. While in the
proliferative phase, the migration and proliferation of
keratinocytes, fibroblasts and endothelial cells result
in epithelialization and tissue granulation. At last, ex-
cess collagens in the wound is degraded by proteolytic
enzymes, leading to the completion of tissue repair in
the remodeling phase.1 Fibrocytes are a novel cell popu-
lation that is derived from peripheral blood mononuclear
cells2 and displays fibroblast-like properties.3 This re-
view focused on the maturation, differentiation, migra-
tion of fibrocytes and their roles in antigen-presenting
and wound healing.
The discovery, phenotype and origin of fibrocytes
  In 1994, Bucala et al3 investigated the cell popula-
tion presented in subcutaneous wound chamber con-
sisting of short length of sponge-filled, silastic tubings
and found a new population of cell type which showed
properties of fibroblasts and expressed instinct leuko-
cyte cell surface markers, CD34 and collagen I. And
then they termed the new leukocyte subpopulation as
“fibrocytes”. After the discovery of fibrocytes, the phe-
notypic characteristics of these cells were further evalu-
ated in many studies. The markers of human fibrocytes
are shown in Table 1.4 It was found that fibrocytes co-
express hematopoietic stem cell antigens and mark-
ers of the monocyte linage, such as CD45, MHCII,
CD34, CD13, CD11b, CD32 and CD64. They also ex-
press fibroblast products including collagen I and
fibronectin. However, the fibrocytes do not express the
markers of T cells (CD3, CD4, CD8, CD25 and CD56)
or the B cell antigen CD19. Therefore, the expression
of CD45 or one of hematopoietic (CD34) or myeloid
antigens (CD13, CD11b) is considered as sufficient cri-
teria to distinguish fibrocytes from leukocytes, dendritic
cells, endothelial cells and tissue resident fibroblasts
in vivo and in vitro.2,5,6 In addition, human fibrocytes also
express several CCRs and CXC chemokine receptors,
including CCR3, CCR5, CCR7 and CXCR4.
The precise origin of fibrocytes has puzzled many
researchers. So far there are two hypothesis. Based
on the number of fibrocytes isolated from peripheral
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blood, the first hypothesis states that fibrocytes com-
prise 0.1%-0.5% of nonerythrocytic cells.3,7 But the sec-
ond hypothesis indicates that human fibrocytes are not
present in peripheral blood and originate from a circu-
lating precursor.5, 6, 8, 9 In other words, there is a mediate
stage between monocytes and fibrocytes, termed as
fibrocytes precursors. Abe2 and his colleagues showed
that the fibrocytes isolated from blood are differentiated
from CD14+/CD16- monocytes. However, it should be
noted that these monocytes contain a mixture of other
precursors which can differentiate into a number of cells
different from macrophages and dendritic cells, such
as myoblasts, osteoblasts, epithelial cells and so on.10,11
Therefore, these fibrocyte precursors may be present
in a small portion of monocyte subset, which is an im-
mature group presenting in the circulation and termed
as “ inflammatory monocytes”.12 In absence of
inflammation, they may serve to replenish the tissue-
resident macrophages and dendritic cell populations
after an initial differentiation into different subtypes of
monocytes before entering the tissue. During the in-
flammatory process, they are released in large amount
from bone marrow into peripheral blood and directly mi-
grate to inflamed sites.12, 13
Maturation and differentiation of fibrocytes
The CD14+/CD16- monocytes are immature cells
which can be differentiated into mature fibrocytes un-
der certain permissive condition. In vitro studies dem-
onstrated that the mature fibrocytes are developed from
peripheral blood monocytes after 10-14 days of culture
in media containing serum and after 3 days in serum-
free media. There are several factors affecting the pro-
cess of maturation.2,5,6,9,14,15 Direct contact between pe-
ripheral blood CD14+ monocytes and T lymphocytes in
co-culture and stimulation of peripheral blood CD14+
monocytes with TGF-β increases the production of
fibrocytes.2,15 Platelet-derived growth factor (PDGF),
interleukin (IL) -4 and IL-13 also promote the differentia-
tion of CD14+ monocytes into fibrocytes.9,16 However,
aggregated IgG or serum amyloid P (SAP) inhibits the
development of mature fibrocytes from the CD14+
monocytes.5,6 SAP, a member of the pentraxin family
of proteins, circulates in blood as stable pentamers.17 Pro-
inflammatory cytokines like interferon-γ(IFN-γ) and
IL-12 also inhibit the differentiation of fibrocytes from
CD14+ monocytes.16 IL-1β can not affect the process,
but it induces the proliferation of mature fibrocytes and
reduces the release of collagens from these cells.16 It
is also reported that exogenous administration of
leukotriene (LT) D4 induces proliferation of murine and
human fibrocytes in a dose-dependent manner.18
When fibrocytes have finished their maturation from
CD14+ monocytes, they will possess the plasticity to
differentiate into fibroblasts and myofibroblasts, which
is promoted by transforming growth factor (TGF) β2 or
endothelin-1 (ET-1)14. Hong19 and his colleagues dem-
onstrated that TGF-βdrives fibrocyte-to-myofibroblast
differentiation through activating Smad 2/3 and SAPK/
JNK MAPK pathway, which in turn stimulates α-smooth
muscle actin expression. But in this process of
fibrocytes differentiation, the expression of CD34 and
CD45 will be down-regulated.3,5,6,19 Moreover, the
profibrotic cytokines, IL-4 and IL-13, promote fibrocyte
differentiation to α-SMA positive cells, such as
myof ibroblasts, from PMBCs without inducing
proliferation,21 whereas the antifibrotic cytokine, IFN-γ,
inhibits fibrocyte differentiation.21 In addition to the for-
mation of fibroblasts and myofibroblasts from fibrocytes,
the fibrocyte-to-adipocyte differentiation also occurs and
is driven by the peroxisome proliferator-activated recep-
tor (PPAR) γ agonist troglitazone, which is associ-
ated with cytoplasmic lipid accumulation and induction
of a P2 (this process is inhibited by TGF-β).19 Thus, it
appears that the maturation and differentiation of
fibrocytes are influenced by a complex profile of
cytokines within the local microenviroment of tissue
injury.
Migration of fibrocytes
According to previous reports, fibrocytes are accu-
mulated in subcutaneously implanted wound chambers
in mice and in early human cutaneous scar tissues.3
However, the mechanism by which peripheral blood
fibrocytes migrate to specific sites of tissue injury is
obscure. As we know, numerous circulating cells, in-
cluding monocytes, neutrophils and lymphocytes, mi-
grate to tissue location as the result of chemokine-
chemokine receptor interactions.22 So the chemokine
receptors expressed on the surface of fibrocytes are
studied. It is reported that human fibrocytes express
several chemokine receptors, including CCR3, CCR5,
CCR7 and CXCR4 (Table 1). Using both in vitro and in
vivo fibrocyte chemotaxis techniques, Abe23 and col-
leagues found that fibrocytes migrate in response to
secondary lymphoid chemokine (SLC), the ligand for
CCR7. Interestingly, the expression of SLC at sites of
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inflammation has been described. So the CCR7-SLC
interaction may play a role in the migration of fibrocytes.
Among these interactions between chemokines and
chemokine receptors, the CXCR 4-CXCL12 axis plays
an important role in homing of bone marrow-derived pro-
genitor cells.24 In a mouse model of pulmonary fibrosis,
fibrocytes are found to express CXCR4 and migrate in
response to CXCL12 in vitro and in the setting of
bleomycin-induced pulmonary fibrosis in vivo. In the
bleomycin model, antibody-mediated neutralization of
CXCL12 results in reduced fibrocytes recruitment to lung
and decreases collagen deposition.25 The CXCR4-
CXCL12 axis is also important in the trafficking of hu-
man fibrocytes in the setting of living fibrosis. Accord-
ing to the studies of patients with fibrotic interstitial lung
disease, the numbers of CD45, collagen I, CXCR4 posi-
tive fibrocytes were higher than those in healthy controls.
Moreover, the CXCL12 ligand expression was also
markedly elevated in the lung and plasma of patients
with lung fibrosis.26 Those findings taken together sug-
gest that fibrocytes express several chemokine recep-
tors and contribute to the migration to wound sites,
likely through the CXCR-CXCL12 axis.
Fibrocytes as potent antigen presenting cells (APCs)
The skin is a vital barrier to infection or tissue inva-
sion and plays a major role in host immunity.27 If the
barrier is damaged, pathogenic bacteria can easily
invade. At this time, APCs should be recruited to spe-
cific injury sites to initiate the antigen-specific responses
by a class II major histocompatibility complex (MHC)-
dependent pathway. Isolated human fibrocytes express
the cell surface molecules required for antigen
presentation, including MHC molecules (HLA-DP and
HLA-DR), costimulatory molecules (CD80 and CD86)
as well as adhesion molecules (CD11a, CD54 and
CD58).28 The expression levels of these markers by
fibrocytes are similar to those of monocytes. Moreover,
human fibrocytes localized to cutaneous scar tissues
express high levels of HLA-DR in situ, suggesting that
fibrocytes may play an early and critical role in the ini-
tiation of antigen-specific immunity and significantly
expand the importance of these cells in the host re-
sponse to tissue injury, because HLA-DR expression
is considered as a prerequisite for antigen presentation
in vivo.29
Table 1. The markers of human fibrocytes
Marker                     Expression        Marker                   Expression      Marker                 Expression           Marker                 Expression
Leukocyte markers
   CD45
   CD90
   LSP-1
Monocyte markers
   CD11a
   CD11b
   CD13
   CD14
   CD16
   CD32
   CD64
MHC molecules
   Class I
   Class II
++
-
++
++
++
++
+/-
-
++
++
++
++
Receptor molecules
   CCR1
   CCR2
   CCR3
   CCR4
   CCR5
   CCR6
   CCR7
   CCR9
   CXCR1
   CXCR2
   CXCR3
   CXCR4
   CXCR5
   CXCR6
+
-
+
+
+
-
+
+
++
-
++
+
-
-
Stem cell markers
   CD34
   CD105
Integrins
   CD18
   CD29
   CD49a
   CD49b
   CD49c
   CD49d
   CD49e
   CD49f
   CD61
   CD163
 α4β7
++
++
++
++
+
++
-
-
++
-
++
-
-
Costimulatory
molecules
   CD40
   CD80
   CD86
B cell markers
   CD19
Fibroblasts production
   Collagen I
   Fibronectin
   Vimentin
   MMP-9
Others
   CD70
   vWF
+
+
++
-
+
+
++
++
-
-
“-”represents no expression; “+/-”represents being expressed or not; “++” represents the increasing level of expression.
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Chesney28 and colleagues tested the capacity of
both human and mouse fibrocytes to present antigens
and stimulate antigen-specific T lymphocytes in vitro.
Human fibrocytes induced antigen-presenting cell-de-
pendent T cell proliferation when cultured with tetanus
toxoid, suggesting that fibrocytes play a role in the ini-
tiation of antigen-specific immunity. The antigen-pre-
senting capacity in vitro of fibrocytes was higher than
that of monocytes and lower than dendritic cells when
assessed by peak antigen-dependent T cell proliferation.
In addition, fibrocytes secrete MIP-1αand MIP-1β,
potent chemoattractant molecules for CD4+ T cells.
These CD4+ T cells are considered essential for the
generation of an antigen-specific response in vivo.28
Thus, fibrocytes may contribute to the host defense
response during tissue injury by recruiting and activat-
ing T lymphocytes to sites of injury.
Fibrocytes can present antigen to CD4+ T
lymphocytes, but no information is available about their
capacity to stimulate CD8+ cytolytic T lymphocyte (CTL)
responses. So Balmelli30 and colleagues isolated
fibrocytes from porcine blood and found that primary
fibrocytes endocytose and degrade antigens efficiently.
But in absence of exogenous stimuli, endocytosis and
MHC II expression are lost. Furthermore, fibrocytes can
stimulate CD8+ T lymphocyte proliferation even at low
Fb/T lymphocyte ratios, at which dendritic cells were
less efficient.30 It is demonstrated from their experiment
that fibrocytes can stimulate the proliferation of CD8+ T
lymphocytes in addition to being capable of stimulat-
ing antigen-specific CD4+ T lymphocytes.
The role of fibrocytes in wound healing
Fibrocytes promote angiogenesis    In the nor-
mal process of wound healing, angiogenesis is a criti-
cal event, by which the cell debris can be easily re-
moved and it can form a wound bed for the develop-
ment of granulation tissue in vivo.22 And the wound-re-
lated angiogenesis appears to be regulated by the in-
teraction of endothelial cells and extracellular matrix
within the wound space.31 Although numerous mediators,
such as growth factors, cytokines and several enzymes,
have been identified to promote angiogenesis, how the
microenviroment of cells affect the angiogenesis is still
obscure. Afterwards, based on the investigation of
fibrocytes, it can be found that fibrocytes secrete VEGF,
PDGF, IL-1β, hematopoietic growth factors and bFGF,
which can promote the endothelial cell proliferation.32
Furthermore, culture supernatants obtained from
fibrocytes promote the migration and differentiation of
endothelial cells in vitro.32
The proteolysis of the basement membrane is also
involved in the invasion stage of angiogenesis. Previ-
ous studies have shown that matrix metaloproteinases
(MMPs) mediate the dissolution of basement membrane
during early tissue repair and initiate angiogenesis.22
MMP-9 is the main MMP found in wound fluid with peak
activity expressed between 2 and 4 days after injury.33
Consistent with these observation, fibrocytes home to
cutaneous wound sites in vivo within 1-4 days, and ex vivo
cultured fibrocytes constitutively express MMP-9 messen-
ger RNA and secrete high levels of active MMP-9.3,32 Be-
sides both autologous fibrocytes and fibrocyte-condi-
tioned media were found to promote blood vessel for-
mation in vivo. These data taken together suggest that
cultured fibrocytes secrete factors that promote an an-
giogenic phenotype in endothelia cells in vitro and an-
giogenesis in vivo.
Fibrocytes secret extracellular matrix molecules
and are the important source of myofibroblasts in
wound    During wound healing, it is essential for re-
parative cells to secret several ECMs in promoting the
healing process. In vitro fibrocytes express numerous
extracellular matrix molecules, including vimentin,
fibronectin and collagen I. But it should be noted that
the secreting process of extracellular matrix must be
regulated by several mediators. If the process is out of
control, the wound healing will be delayed, causing scars
and fibrosis diseases, such as nephrogenic systemic
fibrosis,34-37 interstitial pulmonary fibrosis,38-40 sclero-
derma41 and so on.
In addition, it is reported that myofibroblasts tran-
siently found at the sites of tissue injury are believed to
play a pivotal role in wound healing, but their origin is
poorly understood. Abe2 and colleagues investigated
the ex vivo cultured precursor fibrocytes and found that
they have the capacity to differentiate into α-SMA,TGF-
β1-responsive fibrocytes that exhibit characteristics
similar to those of myofibroblasts, which exert a con-
tractile force for wound closure. Moreover, Luca42 and
his colleagues examined the phenotype of fibrocytes
and myofibroblasts present in wound skin of mice and
found that 61.4% of fibrocytes became α-SMA-posi-
tive between 4 and 7 days after injury, indicating that
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the circulating fibrocytes contribute to the myofibroblasts
population in the wound skin. Therefore, fibrocytes may
be the main source of the myofibroblasts within wound
space.
Conclusion
A growing body of literature over the last decade
has revealed that human fibrocytes may play an impor-
tant role in wound repair. A complex profile of cytokines
within the local microenviroment of tissue injury pro-
mote or inhibit the maturation of fibrocytes and their
differentiation into mesenchymocyte lineage, such as
fibroblasts, myofibroblasts and adipocytes. The
fibrocytes reach the injury sites with the interaction
between the chemokines and chemokin receptors. They
may also promote endothelial cell proliferation, migra-
tion and angiogenesis or contribute to wound closure
by secreting extracellular matrix component. If tissue
infection occurs in wound healing process, fibrocytes
can be potent APCs which are able to recruit and activate
T cells. However, it should be noted that too many
fibrocytes within the damaged tissue may result in fi-
brosis and scarring. Therefore, additional research is
needed to determine the check point between the wound
healing and pro-fibrotic abilities of the fibrocytes.
Moreover, the mechanism by which fibrocytes migrate
to the injured sites is also need to be further investigated,
which may contribute to the improvement of the abili-
ties of tissue wound repair in vivo.
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